Még nem toboroz
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
NCT07791732· 3. fázis· Daiichi Sankyo· Forrás
Még nem toboroz
Fasten Onco Digital Therapy During Neoadjuvant Treatment for Triple-Negative Breast Cancer
NCT07884721· FASTEN· Forrás
Contact: Olfa Derbel, MD (principal investigator)
Toboroz
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00· 3. fázis· Incyte Corp.· Forrás
Még nem toboroz
Multicenter phase III non-Inferiority trial of treatment reduction in patients with advanced hormonesensitive breast cancer in complete response
2026-526319-12-00· 3. fázis· Unicancer· Forrás
Még nem toboroz
Safety and Efficacy of Nivolumab and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients
NCT07679841· 1/2. fázis· Centre Leon Berard· Forrás
Még nem toboroz
Testing Two Different Drugs (Sacituzumab-govitecan and Trastuzumab-deruxtecan) Combinations Prescribed in an Alterning Pattern to Patients With Metastatic or Locally Advanced Triple-negative Breast Cancer
NCT07151586· 2. fázis· UNICANCER· Forrás
Toboroz
Personalizing chemotherapy selection after surgery for patients with stage III colorectal cancer using a blood test
2025-521045-24-00· 3. fázis· Unicancer· Forrás
Még nem toboroz
Assessment of SMI (Superb Microvascular Imaging) for Characterising the Endocystic Material of Papillary Intraductal Mucinous Pancreatic Tumours (PIMPT)
NCT07663734· GCS Ramsay Santé pour l'Enseignement et la Recherche· Forrás
Contact: Bertrand NAPOLEON, MD
Toboroz
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07562152· 3. fázis· Immuneering Corporation· Forrás
Toboroz
Assessment of the Usefulness of SMI (Superb Vascular Imaging) for the Characterisation of Pancreatic Cystic Tumours (IMAKYST)
NCT07657884· GCS Ramsay Santé pour l'Enseignement et la Recherche· Forrás
Contact: Bertrand NAPOLEON, MD
Toboroz
Study aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab)
2023-506291-28-00· 3. fázis· Centre Leon Berard· Forrás
Toboroz
Superb Microvascular Imaging (SMI) and Two-Dimensional Endoscopic Ultrasound Guided Shear Wave Elastography (2D-SWE-EUS) in Differential Diagnosis of Pancreatic Adenocarcinoma (PA) From Other Pancreatic Solid Lesions (PSLs) and Pancreatic neuroendocrinE Tumors (pNETs) Malignancy
NCT07274657· GCS Ramsay Santé pour l'Enseignement et la Recherche· Forrás
Contact: Rodica Gincul, MD
Még nem toboroz
Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer
NCT07150403· 2. fázis· Federation Francophone de Cancerologie Digestive· Forrás
Toboroz
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336· 3. fázis· Eli Lilly and Company· Forrás
Contact: Olfa DERBEL (principal investigator)
Toboroz
Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX
NCT07044453· 2/3. fázis· University Hospital, Rouen· Forrás
Toboroz
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
NCT06346197· 3. fázis· Centre Leon Berard· Forrás
Contact: Chloé VERNET, Dr
Még nem toboroz
PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma
NCT07128290· 2. fázis· Federation Francophone de Cancerologie Digestive· Forrás
Toboroz
Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.
NCT07407465· 2. fázis· Gruppo Oncologico del Nord-Ovest· Forrás
Még nem toboroz
BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients
NCT07071844· 2. fázis· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás
Contact: Jérôme DESRAME, MD
Toboroz
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521· 3. fázis· Relay Therapeutics, Inc.· Forrás
Toboroz
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336· 3. fázis· AstraZeneca· Forrás
Toboroz
Detecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd Therapy
NCT06680596· 2. fázis· UNICANCER· Forrás
Toboroz
Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer
NCT06606730· 3. fázis· UNICANCER· Forrás
Toboroz
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
NCT06501482· 3. fázis· Assistance Publique - Hôpitaux de Paris· Forrás
Toboroz
Comparison of the Occurrence of Postoperative Complications Between Robotic and Laparoscopic Surgery in Revision Bariatric Surgery
NCT07180316· GCS Ramsay Santé pour l'Enseignement et la Recherche· Forrás
Contact: Aminah Dr EL BOUYOUSFI
Toboroz
Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer
2024-513122-27-00· 3. fázis· Daiichi Sankyo Inc.· Forrás
Toboroz
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás
Toboroz
Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer
NCT06245356· 2. fázis· UNICANCER· Forrás
Toboroz
Chimiothérapie à base de bevacizumab adaptée à la pharmacocinétique du bevacizumab en 1ère ligne de traitement du cancer colorectal métastatique non résécable : étude de phase 3 randomisée multicentrique en double aveugle.
2023-507873-16-00· 4. fázis· Centre Hospitalier Regional Universitaire De Tours· Forrás
Toboroz
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
NCT06731478· 3. fázis· Daiichi Sankyo· Forrás
Toboroz
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
2022-502352-31-00· 3. fázis· Amgen Inc.· Forrás
Toboroz
PRODIGE 90 - FFCD 22024 - PREDIR-NEOREC - Neoadjuvant dostarlimab with short course radiotherapy in a watch-and-wait strategy for microsatellite unstable or mismatch repair-deficient locally advanced rectal cancer patients: a randomized phase II trial
2024-510772-20-00· 2. fázis· Centre Hospitalier Universitaire De Dijon· Forrás
Toboroz
Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme
NCT06475352· 2. fázis· UNICANCER· Forrás
Contact: Jérome DESRAME, Dr. (principal investigator)
Még nem toboroz
Medico-economic Evaluation of the Creation of Arteriovenous Access for Hemodialysis Between Surgical Technique and Endovascular Technique in Patients with End-stage Renal Disease
NCT06679907· University Hospital, Bordeaux· Forrás
Contact: Guillaume DANIEL Guillaume
Toboroz
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
NCT06078384· 2. fázis· UNICANCER· Forrás
Toboroz
REPROGRAM-02 : Induction Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin followed by chemotherapy in second line metastatic colorectal cancer carcinoma
2024-516709-22-00· 2/3. fázis· Centre Hospitalier Regional Universitaire· Forrás
Toboroz
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
NCT06572735· Hospices Civils de Lyon· Forrás
Contact: Olfa DR DERBEL
Toboroz
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357· 3. fázis· AstraZeneca· Forrás
Toboroz
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
NCT06476184· 3. fázis· ARCAGY/ GINECO GROUP· Forrás
Contact: Olfa DERBEL MILED
Fut, nem toboroz
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and
immunotherapy ( Pembrolizumab)
NCT04262687· 2. fázis· Fondation Franc.Cancerologie Digestive· Forrás
Toboroz
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649· 3. fázis· Amgen· Forrás
Toboroz
CARE : Impact of Regorafenib in combination with multimodal metronomic chemotherapy (cyclophosphamide, capecitabine, and low-dose aspirin) on progression-free survival compared with standard Regorafenib for the treatment of chemo-resistant metastatic colorectal cancers
2023-509761-21-00· 3. fázis· Centre Hospitalier Regional Universitaire· Forrás
Toboroz
First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer
NCT06253611· 2. fázis· GERCOR - Multidisciplinary Oncology Cooperative Group· Forrás
Contact: Pascal ARTRU, MD
Fut, nem toboroz
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
NCT06346392· 3. fázis· AstraZeneca· Forrás
Toboroz
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200· 3. fázis· GlaxoSmithKline· Forrás
Toboroz
A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer
NCT05639413· UNICANCER· Forrás
Contact: Emilie BRUMENT
Fut, nem toboroz
Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer
NCT05462613· 2/3. fázis· Centre Hospitalier Universitaire de Besancon· Forrás
Fut, nem toboroz
An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
NCT05876754· 3. fázis· Servier Affaires Médicales· Forrás
Fut, nem toboroz
An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma
2022-501463-40-01· 3. fázis· Servier Affaires Medicales· Forrás
Showing 50 of 82.